CHEK2 and breast cancer: The case–control analysis revealed that the breast cancer risk of functionally impaired germline variants is comparable with that of truncating CHEK2 P/LP variants and suggested that the clinical management of (breast) cancer prevention in both groups of carriers should be similar (37).